Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic cou...
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
About this item
Full title
Author / Creator
Publisher
Italy: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Italy: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011-2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registries have been established in both Finland and Sweden. Our stud...
Alternative Titles
Full title
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b5466693b9c645da8755df43b022b865
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b5466693b9c645da8755df43b022b865
Other Identifiers
ISSN
2049-6958,1828-695X
E-ISSN
2049-6958
DOI
10.1186/s40248-018-0126-7
